← Back to markets
Arbutus Biopharma
ABUS · Health Care · Biotechnology
$5.20
RS +16.3
Returns
| 7D | +10.4% |
| 1M | +18.7% |
| 3M | +19.5% |
| 6M | +18.5% |
| YTD | +8.1% |
| 1Y | +45.3% |
About Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.